Form S-8 Fulcrum Therapeutics,
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- Wall St to open higher on Mideast deal hopes; SpaceX debut in focus
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Oil falls to near two-month lows as Trump calls off threatened strikes on Iran
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Wall St set to gain on tech rebound, Middle East in focus
Stifel on Fulcrum Therapeutics (FULC): 'we think overly nitpicking 19.3% is splitting hairs and misses the bigger picture'
February 24, 2026 10:23 AM ESTStifel analyst Dae Gon Ha reiterated a Buy rating and $25.00 price target on Fulcrum Therapeutics (NASDAQ: FULC).
The analyst comments "The move this morning surprises us. While we think some thought total mean HbF may comfortably be >20% given the strength of the... More
